Posted inEmergency Medicine news Psychiatry
Injectable vs. Sublingual Buprenorphine: Shaping the Future of Emergency OUD Care
The ED INNOVATION trial reveals that 7-day extended-release injectable buprenorphine is safe and as effective as sublingual formulations for treatment engagement, offering significant benefits in craving reduction and patient satisfaction even in fentanyl-prevalent environments.



















